ENLIBRIUM

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.